Abstract: Mesenchymal stromal cells (MSCs) participate in repair of damaged tissues, possess the potential to serve as a useful tool in the drug discovery field and exert immunosuppressive effects as demonstrated by their ability to modulate the immune response. Herein, the roles played by MSC differentiation and/or production of trophic factors involved in tissue repair are discussed. MSCs offer the opportunity to probe targets that conventional or differentiated cell lines do not express; thus providing a more refined system that allows identification of novel therapeutics. However, there are difficulties associated with drug discovery assays to which MSCs are not exempt. The immunosuppressive potential of MSCs has already been utilised in clinical trials where MSCs have been used to treat patients with graft-versus-host disease (GvHD) and autoimmune diseases. Another possible therapeutic application of MSCs lies in the field of transplantation tolerance. Although the capacity of MSCs to modulate immune responses has received much attention, the role of MSCs in transplantation tolerance is as yet unclear. In this review, we discuss the evidence for MSC induction of a state of tolerance in the transplantation setting.
TISSUE REPAIR AND REGENERATION
In evolutionary terms, the appearance of multicellular organisms with specialised tissues and organs created a profound challenge; the need to regenerate or restore damaged tissue. Tissue regeneration is the solution to this problem and is seen most dramatically in amphibians [1, 2] . Here physiological damage can induce a regenerative process that restores both organ architecture and function. The fields of regenerative medicine and human tissue engineering seek to harness the mammalian counterparts of such processes for therapeutic use in humans. In mammalian systems studied to date, such processes rely on a complex interaction of nondifferentiated cells and trophic factors at the site of damage [3, 4] . The precise nature of such complex interactions varies by disease/injury, target organ, species, age and other parallel reparative processes. These processes may involve dedifferentiation of damaged tissue, trans-differentiation of progenitor cells, cell fusion, or differentiation of precursor stem cells [3] . As tissue resident and bone marrow derived stem and progenitor cells can contribute to regeneration, cells such as bone marrow derived mesenchymal stem cells (MSCs) have become a major feature of regenerative medicine, and the basis of a rapidly growing industrial sector based on cell therapy [5, 6] .
tic-adherent cells (under standard culture conditions) that express CD73, CD90 and CD105 but not the hematopoietic markers CD11a, CD19, CD34, CD45, or HLA-DR [20, 21] . In addition to qualify as MSCs, isolated cells should demonstrate the capacity to differentiate into osteocytes, adipocytes, and chondrocytes in vitro when suitably stimulated [20, 21] . It is important that researchers in drug discovery or research programs adhere to rigorous quality control regarding MSCs, as populations can lose multipotency with passage [22, 23] . Even so, it is likely that the ISCT definition allows groups to work with heterogenous populations that may include mixtures of genuine stem cells with other cells that are more likely committed progenitors, perhaps accounting for variability in some published data. More seriously, groups which fail to repeatedly monitor for hematopoietic contamination may be generating data of little value. While MSCs from different sources share differentiation capacity (adipocytes, osteoblasts and chrondrocytes) as well as phenotypic markers [24] , more rigorous functional assays have identified clear differences in function. In particular, MSC derived from bone marrow and synovium were more effective in inducing repair in cartilage defect models than those from adipose or skeletal muscle [25] . Importantly, MSC derived from dental pulp but not those derived from adipose or bone marrow generate dentin [26] . Whereas the capacity to differentiate into osteocytes, adipocytes, and chondrocytes are defining features of MSCs in vitro, more potent transdifferentiation has been described. MSCs can be driven to differentiate into myocytes, endothelium, cardiomyocytes, fibroblasts, neural cells, and possibly hepatocytes, epithelium or even insulin producing cells, depending on the stimuli [27] [28] [29] [30] [31] [32] [33] [34] [35] . This multipotentiality combined with the ease of culture and expansion, have led to MSCs becoming a lead therapeutic in the race for cell based regenerative therapies [6, 36] .
Tissue Repair Through Direct Differentiation or Transdifferentiation
MSCs have been used as regenerative cell therapies in numerous experimental models. For example, site directed administration of bone marrow MSCs to infarcted myocardium resulted in the regeneration of the injured tissue [37] [38] [39] [40] . Furthermore mouse MSCs delivered into healthy adult myocardium resulted in the formation of new blood vessels in which donor cells were identifiable after transplantation [41, 42] . Transplanted MSCs had differentiated in situ to several cell types including cardiomyocytes, endothelial cells, pericytes and smooth muscle cells [41] . Using single cell marking this group also showed that cardiomyocytes were most likely to have been generated stochastically from a single-cell-derived stem cell [42] . Similarly, in porcine models, MSCs have been shown to engraft into the host myocardium and differentiated to myogenic cells, reduce infarct size, and support other physiological improvements [43] . These observations are supported by studies suggesting that MSCs can engraft in vivo in bone, lungs, and liver [11, [44] [45] [46] , and that MSCs (in demineralised bone or other matrices) contribute to bone growth and repair [47] [48] [49] . In rodent models of acute renal failure, male MSCs protected female recipients from induced pathology and male cells were not only localized to tubular epithelium but also expressed characteristic lectins [50, 51] , these and other studies support local engraftment and differentiation into tubular epithelial cells.
MSCs can contribute to regeneration of ectodermal, mesodermal and endodermal tissues (reviewed in [52] ), however these effects might be attributable to mechanisms other than differentiation. Indeed, the evidence for true MSC engraftment and direct reconstitution by MSC differentiation in vivo is currently not extensive despite the vast literature on these cells. Even in myocardial infarction models, both the level of engraftment and the number of MSC derived cardiomyocytes seems to be too low to fully explain the therapeutic benefit, and likewise the beneficial effects of MSCs in acute ischemic renal disease models appears to be through differentiation-independent mechanisms [53] [54] [55] [56] [57] .
Tissue Repair Mediated by Trophic Factors
A conceptual advance in this debate came when it was proposed that much of the therapeutic benefit of MSCs was associated with the release of soluble factors that acted in a paracrine manner to promote repair [58, 59] . Thus MSCs might be considered as trophic agents, which guide or "nourish" the process of tissue repair rather than, or in addition to, direct differentiation and regeneration. Of course if MSCs are heterogeneous mixed populations, it is possible that trophic action and differentiation are not mutually exclusive, or that different trophic effects may be performed by different sub-populations. The term "trophic effect" encompasses many functional characteristics of MSCs such as immunomodulation (see below) as well as anti-apopototic, cytoprotective effects and the promotion of angiogenesis [58] . The latter may be an important component of repair as it is known that vascular stability contributes to healing and that pericytes (mural cells) contribute to this [60] . Interestingly, MSCs express some pericyte markers and it has been proposed that tissue resident MSCs may be derived from perivascular precursors [16, 47, 61, 62] . MSCs can also express VEGF [63] and therefore may be intimately involved in neovascularisation of wounds and suggesting this to be a key trophic contribution to regeneration.
Effect of Licensing on MSC Potency
There is still a great deal to be discovered about the regenerative process and the role of MSCs. Indeed much may still be learned from comparative systems in amphibians and other animals [1, 2, 4] . These and other studies have shown that regeneration requires tissue resident stem cells of different potency and type supported by complex trophic factors at the site of damage. A process that is more subtle and broad than current models of MSC regeneration. Perhaps most interesting is the demonstration by Lucas et al that the inflammatory process (linked to tissue damage) characterised by neutrophil and macrophage influx, was essential to regeneration (reviewed in [1, 2] ). These studies indicated that a complex mixture of progenitor cells (including fibrogenic and myofibrogenic progenitors, lineage committed stem cells and uncommitted pluripotent stem cells) were involved in the process. Inflammation was important for debridement and reserve/stem cell activation [1, 2] . This is strikingly similar to the concept of "licensing" that has been proposed for mouse and human MSCs. Licensing suggests that MSCs are acti-vated and enhanced by inflammatory signals such as IFNat the site of repair and that such licensing enhances the regenerative process [64] . This is supported by data from numerous groups showing that inflammatory mediators generally do not break the immunosuppressive nature of MSCs but rather enhance it [65] [66] [67] [68] [69] . The implication being that future cell therapy may benefit from pre-stimulation of MSCs.
The trophic influence of MSCs is likely to extend to other aspects of the repair process as well. For example, MSCs have a profound suppressive influence on fibrosis in vivo [70, 71] . This may well be linked to the observation that human and mouse MSCs express the anti-fibrotic factor HGF and this is also upregulated by IFN-prestimulation/licensing [55, 64, 68, 72] . Clearly MSCs play a complex role in tissue repair and these roles are achieved via multiple mechanisms. Overall regeneration and engraftment probably play a much smaller part than previously anticipated in the regenerative processes mediated by MSCs. Indeed features such as the anti-fibrotic effect and the powerful immune modulation that can be achieved by MSCs suggest that cell therapies using these cells may find most success against targets such as the chronic autoimmune diseases. However, it is important to note that MSC therapy is not a panacea. In particular the influence of MSCs on fibrosis will require further study as MSCs can also express pro-fibrotic factors or promote fibrogenesis indirectly through differentiation into myofibroblasts [73] . Moreover MSC associated immune suppression can provide increased risk of infection in patients as has been documented in GvHD trials [74] .
DRUG DISCOVERY
Current drug discovery programs rely on early stage, high throughput, hit identification protocols based on in vitro models. Indeed cell based in vitro systems contribute to hit identification, target validation, lead selection, as well as informing protocols around ADME-Tox. The disappointing late stage attrition of leads suggests that more refined approaches are now required [75] . Most current drug discovery systems are based on established transformed cell lines or specific primary cultures. Such lines have proved useful in addressing questions of pharmacological performance and safety, having the great advantage of near limitless scalability. However these cell systems are of abnormal genotype (neoplastically transformed), are tissue lineage restricted, show abnormal physiological and growth characteristics and it is not surprising that stem cell approaches are being examined to improve these programs and to enhance the discovery process [75] .
Advantages of MSC based Drug Discovery Platform
Certainly, the greatest drug discovery potential lies in 'pluripotent' human embryonic stem cells (hESCs) and in human somatic cells that have been reprogrammed into induced pluripotent stem cells (iPSCs) with embryonic stem cell properties [75] [76] [77] [78] . Drug discovery based on these cells is likely to become a main stream component of all pharmaceutical discovery strategies in the near future [77] [78] [79] [80] . Indeed MSC based approaches are already in use [81] [82] [83] and have major advantages over conventional non-candidate based hit identification programs. MSCs are not transformed, have less restricted lineage limitations, and display more relevant growth/ cell division characteristics [7, 59] . In particular the expandability of umbilical cord MSCs derived from Wharton's jelly make these cells good candidates for inclusion in high throughput screening (HTS) systems [18, 52] . The current applications for MSCs are in compound screens, to probe structure-activity relationships, in the conversion of hits to leads and in supporting or terminating the progression of lead molecules through the development process. This is particularly relevant to discovery programmes aimed at the development of treatments for osteoporosis, obesity, diabetes, metabolic disorders and joint disease, where MSCs provide an opportunity to deliver more targets and process appropriate information. In addition MSC screens may play an important role in the discovery of drugs targeting cancer stem cells or the tumour stroma [84, 85] .
MSC based drug discovery protocols offer opportunities and advantages in two broad areas. The first area concerns targets that are currently difficult to assess. It is necessary to appreciate that certain drug targets may only be expressed at specific times during lineage development or in minority tumour tissue residents. MSCs offer an opportunity to probe such targets at specific differentiation stages whereas conventional or differentiated cell lines do not without extensive manipulation. Thus MSCs offer a more refined and sophisticated system that allows identification of small molecules acting at unique stages of the differentiation process, and/or validation of more subtle (but potentially more relevant) targets [79] [80] 86] . The second area concerns the exploitation of the immune modulatory aspects of MSC biology for drug discovery, an area ripe for exploitation. The major opportunities for drug discovery are associated with two inter-linked disease processes: inflammation and autoimmunity/ transplantation. Inflammation is a key component of the pathological processes of the major diseases requiring new therapies, and targeting inflammation is a major feature of most drug discovery programmes. The potent anti-inflammatory potential of MSC discussed below, allows these cells to be combined with RNAi libraries in high throughput and high content screens, to identify anti-inflammatory candidates and particularly candidate combinations. The use of MSC in drug discovery for novel therapies supporting transplantation or targeting autoimmunity is nascent. However the very recent demonstration that regulatory/tolerogenic T cells are not only induced by MSC but that such cells are effective and necessary at reducing immune mediated pathology in animal models is important [87] . This suggests that MSC may be a rich source of novel tolerogenic and suppressive factors of real value. In effect MSC might be profitably exploited to discover both candidate drugs and novel mechanisms to promote transplant tolerance or suppress autoimmune and hypersensitivity reactions.
The most likely approaches to develop novel screens will combine MSC with RNAi or antagonist libraries. The combination of MSC based high throughput assays with RNAi libraries allows functional screening to be performed with a high level of complexity [88] [89] [90] . A process that offers a rich vein of potential novel hits and leads; however, the assumptions underlying RNAi use in these systems need to be con-sidered carefully. The uptake of siRNA, and the efficacy of silencing are likely to be quite variable in such systems. Furthermore the induction of intrinsic cell processes (such as production of type 1 interferons) can confound interpretation. Nevertheless the combination of more informative MSC assay approaches, extensive silencing libraries, and high throughput assay handling offer a powerful drug discovery tool [88] [89] [90] [91] .
In addition to the MSC based assay system, the choice of readouts needs careful consideration. For differentiation based approaches, these may be relatively straightforward such as the measurement of alkaline phosphatase activity as an early marker of osteogenesis. However the efficient induction of some pathways such as cartilage formation requires MSCs to be cultured in cell pellets, embedded in gels or some other three dimensional matrix. These systems provide additional challenges and may require both large numbers of cells and novel quality control protocols. Nevertheless such approaches have found application in osteoarthritis research, where modulators of early chondrogenic differentiation may be measured by the expression of SOX-9 in MSC pellet cultures [92] . Although not strictly drug discovery, MSC differentiation along the adipogenic pathway [93] [94] might also be used to probe environmental features of pollutants, environmental screening or bio distribution/accumulation in fatty tissue in ADME studies [95] . MSC derived adipocytes can also be used to screen lipolytic agents, or to assess modifiers of lipid accumulation, supporting discovery of novel therapeutic interventions in obesity and diabetes [95] . The selection of readouts for immunological indicators will also be very dependent on the disease indication of interest. It is quite feasible that if inflammation is the target then MSC approaches can be adapted to the myriad of systems in current use. However future discovery based on tolerance induction or suppressor activity by MSC (discussed below) may well require new high content and high throughput approaches perhaps based on second cell readouts (dendritic cell or regulatory T cell) or more likely reporter approaches (such as FOX P3 expression).
Limitations of MSC based Drug Discovery Platform
The benefits of MSC based drug discovery are challenged by two major difficulties: assay reproducibility and robustness, both of which have limited the wider application of MSC based assays [96] . Bone marrow derived MSCs show both donor-to-donor and lot-to-lot variability in proliferation and differentiation potential; features which cause considerable trepidation when designing a drug discovery strategy and this might be especially problematic for immunological indications. Unfortunately the difficulties do not end there, as MSCs defined by the ISCT and isolated by most published protocols are a heterogeneous mixture of similar mesenchymal cells, possibly containing more potent and stem like populations, along with cells with reduced potential, pre-committed to single or dual lineages. Furthermore heterogeneity in populations is compounded by other features of differentiation. For example, even in adipocyte promoting conditions, a considerable percentage (30 -40%) of cells in a bone marrow derived MSC culture remain undifferentiated [97, 98] . Whilst these variations in potential provide a system-based robustness to the repair response in vivo, in the context of drug discovery such heterogeneity of response creates serious challenges. Another related difficulty is that differentiation of MSCs to some cells such as cardiomyocytes can be relatively inefficient using current protocols. Thus screening processes need to operate when only small numbers of the specialised cells (signal) are produced against a non-differentiated background (noise) [96] .
New Readout Systems
It is fortunate that recent advances in automated imaging and data processing have allowed the development of multiparameter endpoint quantitation techniques and helped to overcome some of the difficulties outlined above. The most widespread approaches have been termed high content screening (HCS) but may also be known as cell based screening, phenotypic screening or visual screening [88] [89] [90] 99, 100] . HCS has been used predominantly as a research tool in industrial and academic situations. A basic example of HCS application is the determination of the effect of a potential drug/chemical on aspects of stem cell differentiation and involves the combination of live cell imaging with sophisticated image analysis [86] . This research platform offers the potential to conduct large scale cell based screens in a more physiologically relevant experimental format and allows robust assays to be developed in situations where differentiation involves only a subset of the population exploited. Essentially HCS involves 5 steps, assay optimisation for scale up; image acquisition; automated image analysis, data management, data analysis/hit output.
Although HCS optimisation can be time consuming and complex, once attained, robust, reproducible and informative outputs can be achieved and novel hits obtained [101] [102] [103] . Such approaches may seem expensive, but higher quality information obtained early in the discovery process may lead to reduced late stage attrition and higher quality leads, making combined MSC based assays with HCS readouts a feasible platform for novel drug discovery programmes.
MSC IMMUNE MODULATION
The development of MSCs as therapeutic agents has progressed rapidly over the past 5 years and their potential as modulators of the immune responses has ignited great interest in the field. Currently clinical trials focusing on MSCs for treatment of GvHD and autoimmune diseases are underway. One of the areas likely to benefit from the therapeutic effects associated with MSC immune modulation is that of transplantation [104] .
The Impact of MSCs on Transplantation Rejection
To date transplantation remains the most effective treatment for patients with established organ failure. While significant advances in the development of immunosuppressive drugs has allowed the successful clinical application of organ transplantation, there are problems associated with long term administration of non-specific immunosuppressive drugs including increased susceptibility to infection and induction of diabetes, de novo malignancy, cardiovascular complications and renal failure [105] . Consequently, there is a clear requirement for the development of more specific immuno-suppressive therapies that are non-toxic for utilisation in the organ transplantation setting.
A large body of data supports the idea that MSCs can very effectively modulate the immune response both in vitro and in vivo and may therefore serve as a potential source of immunosuppressive therapy [106] . Certainly, data from both pre-clinical models and clinical trials suggest that MSCs have the capacity to modulate the immune response in vivo. However is it not yet clear whether or not MSCs can induce a state of tolerance in the setting of clinical organ transplantation, but the outlook is promising [104] .
Influence of MSC on the Innate Immune Response
The innate immune response provides the first line of defence against infection and encompasses both cellular and non-cellular components including complement activation and the involvement of evolutionarily conserved pathogen recognition receptors (PRRs). In addition, innate immunity is also triggered by danger signals. Although rejection of allogeneic grafts is known to be mediated primarily by T cell and antibody responses [107, 108] , a number of studies now suggest that the innate immune response plays a role in the immune response to solid organ transplantation (reviewed in [109] ).
MSCs used as a cell therapy in any inflammatory setting including organ transplantation will encounter the innate immune response and therefore it is important that we understand how MSCs will interact with these first line responses. Recently Tu et al have demonstrated that human MSCs inhibit complement activation through secretion of factor H (the primary complement inhibitor found in serum) [110] . Furthermore, MSCs have been demonstrated to be responsive to the complement activation products C3a and C5a, leading to migration and activation of MSCs [111] . Clearly, the interactions between MSCs and the complement system require further study, but it seems likely that MSCs are not only protected from deletion by innate mechanisms but are also responsive to such mechanisms; which may be important at sites of tissue injury or ischemia reperfusion injury associated with transplantation.
Toll like receptors (TLRs) are the best studied PRRs and play an important role in activating the innate immune response and subsequent shaping of adaptive immunity [112] . TLRs are found on many hematopoietic cells including B, T, mast cells and dendritic cells (DCs) and expression is augmented by inflammatory mediators and danger signals. MSCs may be exposed to TLR ligands when administered to patients undergoing organ transplantation or indeed in any other inflammatory conditions. MSCs have been reported to express an array of TLRs and it is now clear that TLR signalling has an effect on MSC survival, differentiation, migration and immunosuppressive capacity. TLR3 and TLR4 stimulation prevented the suppressive effect of MSCs on T cell proliferation and this was dependent on the downregulation of the Notch ligand jagged 1 [113] . In contrast, Opitz et al demonstrated that TLR3 and TLR4 ligation enhanced MSC immunomodulation through the indirect induction of IDO1 [65] . A number of studies also report that TLR engagement in MSCs leads to changes in cytokine production [114] [115] [116] and therefore may allow further enhancement of immune suppression mediated by MSCs under certain conditions. Additionally, data demonstrate that ligation of TLR3 and TLR4, enhances MSC proliferation and migration in vitro [116, 117] and augments the efficacy of MSCs in vivo in a rat model of myocardial infarction [118] . In general it appears that TLR signalling does not significantly impact MSC immune suppression or trophic effects, but the consequences of TLR engagement and signalling in MSCs remain to be fully elucidated and therefore the field would benefit from further research in this area.
Although, monocytes/macrophages do not play a direct role in alloantigen presentation and therefore allorecognition; they actively infiltrate the allograft and proliferate in situ [119] , contributing to the production of proinflammatory cytokines, reactive oxygen and nitrogen species [120] . Akin to the capacity of DCs to respond to their local microenvironment and become stimulatory or tolerogenic, monocytes and monocyte derived cells are also responsive to local cues. The best example of this is the generation of alternatively activated macrophages. Recent in vitro and in vivo data provide evidence that MSCs "educate" macrophages through cell-contact dependent cross talk leading to the generation of macrophages with an altered cytokine profile typically secreting IL-10 [121, 122] . Another important role for macrophages is the participation in wound healing [123] , the secretion of trophic factors by MSCs has been shown to recruit these cells in a mouse model of excisional wound healing [124] . Therefore it seems that while MSCs modulate macrophage cytokine profiles, they do not appear to interfere with intrinsic macrophage wound healing properties.
Unlike macrophages, neutrophils can mediate tissue damage directly through the production of cytotoxic granules and pro-inflammatory cytokines. It is recognised that neutrophils infiltrate organs within hours after transplantation in response to surgical trauma or ischemia/reperfusion. MSCs have been shown to indirectly modulate neutrophil migration in a mouse model of sepsis. Interestingly, MSC induced secretion of IL-10 by tissue resident macrophages which subsequently limited the extent of the neutrophil infiltrate [122] . Through in vitro experiments, the authors demonstrate that this process required complex interaction between MSCs and macrophages and involved LPS activation of TLR4 in MSCs, leading to MSC production of PGE-2 which was enhanced by TNF--TNF receptor 1 engagement on MSCs [122] . The capacity for MSCs to directly or indirectly attenuate the infiltration of neutrophils could potentially play an important part in MSC immune modulation of graft rejection and impact positively on the overall goal of the prevention of graft damage in the transplantation setting.
Natural killer (NK) cells can significantly impact the outcome of solid organ transplantation. NK cells are cytotoxic to major histocompatibility complex (MHC) class I mismatched allogeneic cells and target these cells for destruction through contact mediated release of perforin, granzyme and Fas ligand [125] . In addition, NK cells mediate their effector function through production of the proinflammatory cytokines IFN-and TNF-. Early in vitro observations suggested that MSCs were not a target for lysis by freshly isolated NK cells and inhibited NK cell production of IFN- [126, 127] . However, although more recent findings corroborate MSC suppressive effects on NK cell cytokine production, proliferation and effector function [128] , there is some evidence demonstrating that MSCs can be lysed by activated NK cells [128] [129] [130] . Overall, the data discussed herein emphasise the complexity of interaction between MSCs and the innate immune system and highlights the potential for exploiting these effects in the setting of organ transplantation.
Influence of MSCs on DCs
DCs are the primary antigen presenting cells which play a critical role in the activation of the adaptive immune response; specifically the initiation of antigen specific T cell responses. Following organ transplantation, both donor and recipient derived DCs have the capacity to present alloantigen to recipient T cells through the direct and indirect pathways of allorecognition respectively [109, 131] .
As DCs play such an important role in allograft rejection; much attention has focused on the effect that MSCs have on DC development and function. Notably, a number of studies support the idea that MSCs inhibit or interfere with DC differentiation from precursor frequencies [132] [133] [134] [135] . Importantly this effect is reversible and can be mediated by the MSC derived soluble factors IL-6 and PGE-2 [133] . MSCs may encounter DCs at different stages of development and under varying microenvironments and the specific conditions encountered will likely influence the effect that MSCs have on DCs. For example MSCs have differential effects on the generation of conventional DCs and plasmacytoid DCs [136] .
Given the immune suppressive effects of MSCs, it seems likely that MSCs could orchestrate the induction of DCs with a regulatory or tolerogenic phenotype. To this end many studies have repeatedly shown that MSCs indeed induce a tolerogenic-like DC population through down modulation of MHC class II as well as the co-stimulatory molecules CD40, CD80 and CD86 [133, [137] [138] [139] . This tolerogenic DC phenotype induced by MSCs was stable as restimulation with LPS did not reverse the effect. An outcome associated with MSC induction of tolerogenic DCs was a change in cytokine production involving a switch from pro-inflammatory cytokines (IL-12, TNF-) to the anti-inflammatory cytokine (IL-10) [126, 134, 140] . Notably, these MSC induced tolerogenic DCs display regulatory functions in their capacity to suppress the proliferation of rapidly expanding T cells [139] , and to alter the ratio of T cell subsets and the frequency of regulatory T cells (Tregs) [137] [138] [139] [140] [141] .
Interactions between MSCs and the Adaptive Immune Response
While T cell mediated immunity is central in allogeneic rejection mechanisms, humoral or antibody mediated immune responses are also involved [107] [108] . Since the early reports outlining the capacity of MSCs to inhibit T cell proliferation in vitro, the field has progressed rapidly and we now have a greater understanding of how MSCs mediate their effects. A large body of data convincingly demonstrate that MSCs inhibit both alloantigen and mitogen driven T cell proliferation [64, 142, 143] , but recent evidence suggests that MSCs have little effect on virally-driven proliferation [144] .
Importantly, MSC capacity to modulate T cell responses is thought to be dependent on the inflammatory microenvironment present at the time of interaction between these two cell types [66, 145] . Indeed a mechanistic study carried out by Ren and colleagues demonstrated a requirement for IFN-, TNF-and/or IL-1 in the activation of MSC immune suppressive function [145] .
Differentiation of naive helper T cells to specific subsets has also been shown to be altered in the presence of MSCs; skewing towards Tregs and preferential suppression of Th1, Th2 or Th17 depending on the system in question [122, 146, 147] . Support for this scenario has been provided in in vivo models of transplantation and autoimmune diseases where MSCs accommodate the augmentation of T cell subsets in favour of a regulatory environment [141, [147] [148] [149] , and from preclinical models of MSC cell therapy where depletion of CD4+CD25+ FOXP3+ Treg ablated the protective effect of MSC [87] .
Tregs certainly have the potential to induce tolerance in organ transplantation and it is well established that Tregs can control alloreactive T cell responses [150] [151] [152] . Mechanistically, the induction of Tregs by MSCs is an important feature of MSC mediated immunosuppression particularly in the setting of transplantation; where the induction of tolerance to graft associated antigens is the paramount goal. To this end, MSC induced Tregs have been shown to be donor-specific in a mouse model of cardiac allograft rejection [148] . The mechanisms involved in MSC induction of Tregs have been investigated by a number of groups. While cell contact, PGE2 and TGF-have been identified as key mediators [153] , MSC secretion of HLA-G in an -IL-10 and -cell contact dependent manner or in combination with LIF have also been identified to contribute to the expansion of Tregs in vitro in different systems [154, 155] .
Although the majority of studies focus on the effects of MSCs on CD4 + T cells, a small number of reports have demonstrated that MSCs also inhibit CD8 + T cell proliferation [127, 156, 157] . However, there are inconsistencies with regard to data on the effect of MSCs on CD8 + T cell cytotoxicity [127, 157] , which may be explained in part by an effect of MSCs on cell number, possibly through an increase in cell death. Importantly, it seems that MSCs are not targets for destruction by CD8 + T cells [127] .
The other major component of the adaptive immune response is humoral or antibody mediated immunity implemented by B cells. Antibody mediated events have been associated with both acute and chronic rejection [107] . The effects of MSCs on B cell proliferation and function have been reported in vitro, with a small number of studies carried out using in vivo models. Data from the in vitro experiments involving co-culture of MSCs with purified populations of B cells under various stimulatory conditions, primarily demonstrate an inhibitory effect of MSCs on B cell proliferation, differentiation, Immunoglobulin (Ig) production and chemotaxis [158] [159] [160] [161] [162] [163] [164] . So far the mechanisms responsible for MSC modulation of B cell functions have been identified as alternatively cleaved CCL2 [162] or the combined effects of IFN-, cell contact and PD1/PDL1 interaction [163] . In vivo models of pathogenic antibody production have demonstrated the capacity of MSCs to inhibit Ig production (including both T cell dependent and independent antibody responses) in vivo [158, 161, 162] . In contrast, data from others groups focusing on mouse models of SLE did not support these findings; with evidence of MSC failure to suppress auto-antibody production or increased auto-antibody titre and disease activity [163, 165] . The discrepancy between these results may be due to differences in the systems examined (pathogenic versus autoimmune antibody production) or indeed the MSC populations used. Overall, the data highlight the capacity for MSC to modulate plasma cell function but also to stimulate these cells in specific circumstances and therefore emphasises the need for additional research using a number of different in vivo models in conjunction with a defined population of MSCs to provide consistency.
Influence of the Combined Effects of MSC Reparative and Immune Suppressive Capacities
As discussed above, organ transplantation is hampered not only by allogeneic rejection mechanisms but also ischemia/reperfusion or tissue injury associated with surgery. While current immunosuppressive regimens are targeted against the allogeneic rejection pathways; no specific measures are taken to combat the tissue injury common to organ transplantation. The immunosuppressive capabilities of MSCs combined with their inherent reparative functions, provides a possible therapeutic strategy to prevent graft rejection and enhance tissue repair. However, it seems likely that a combination therapy consisting of a brief period of immunosuppression followed by MSCs may facilitate a better outcome than MSCs or conventional immunosuppression alone.
Clearly the best studied clinical application of MSC therapy is in hematopoietic stem cell (HSC) transplantation, either for the enhancement of hematopoietic engraftment or for the treatment/prevention of GvHD. The capacity for MSCs to provide support for haematopoiesis combined with the inherent aptitude to encourage repair through secretion of trophic factors likely contributes to the increased levels and speed of engraftment seen in patients treated with MSCs [166, 167] . As discussed above, one of the most interesting properties of MSCs is their capacity to modulate the immune response and data from clinical trials demonstrate a protective effect mediated by MSCs in patients with steroid resistant acute GvHD [74] . These published findings provide a platform for the use of MSCs in other clinical indications particularly that of organ transplantation. Trials utilising MSCs in solid organ transplantation have recently been initiated and over 100 trials using both the immune modulatory and or reparative effects of MSCs. The results from these trials will provide important insight into the applicability to MSCs in transplantation.
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